Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Bristol-Myers Squibb
Primary purpose: The primary purpose is to assess the pharmacokinetics of a single dose of Dapagliflozin in the range of 2.5 to 10 mg in pediatric subjects aged 10 to 17 years with T2DM
Age
10–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical diagnosis of T2DM
Male and female subjects ages 10-17
Glycosylated Hemoglobin A1c (HbA1c) ≥6 to 10%
Body weight ≥30 kg
You may not be if
Fasting plasma glucose (FPG) \>240 mg/dL at screening
Abnormal renal function
Active liver disease and/or significant abnormal liver function
